Exact Sciences (EXAS) PT Raised to $85 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
Exact Sciences (EXAS) PT Raised to $82 at BTIG
September 16, 2024 3:09 PM EDTBTIG analyst Mark Massaro raised the price target on Exact Sciences (NASDAQ: EXAS) to $82.00 (from $70.00) while maintaining a Buy rating.
The analyst comments "Shares of EXAS are up ~5% today (and +20% in the last few days) following EXAS' blood-based CRC test readout from a ~3,000 patient, partial case control study read out during the European Society of Medical Oncology (ESMO)... More
Citi Reiterates Buy Rating on Exact Sciences (EXAS)
September 16, 2024 8:26 AM EDTCiti analyst Patrick Donnelly reiterated a Buy rating and $80.00 price target on Exact Sciences (NASDAQ: EXAS).
The analyst comments "This morning, EXAS released initial data on their blood-based CRC test at ESMO. The test showed overall CRC sensitivity of 88.3%, specificity of 90.1%, and AA... More
